These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 19808302)
1. Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Guazzi M Circ Heart Fail; 2008 Nov; 1(4):272-80. PubMed ID: 19808302 [No Abstract] [Full Text] [Related]
2. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. Botha P; Parry G; Dark JH; Macgowan GA J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695 [TBL] [Abstract][Full Text] [Related]
3. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Kapur V; Chien CV; Fuess JE; Schwarz ER Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278 [TBL] [Abstract][Full Text] [Related]
4. New inotropic drugs for treatment of congestive heart failure. Schwertz DW; Piano MR Cardiovasc Nurs; 1990; 26(2):7-12; discussion 12. PubMed ID: 1969769 [No Abstract] [Full Text] [Related]
5. Phosphodiesterase inhibitors. Do the risks outweight the benefits? Andrews R; Cowley AJ Drug Saf; 1993 Dec; 9(6):404-9. PubMed ID: 8129862 [TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Kumar P; Francis GS; Tang WH Nat Rev Cardiol; 2009 May; 6(5):349-55. PubMed ID: 19377497 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure. Van Tassell BW; Radwanski P; Movsesian M; Munger MA Pharmacotherapy; 2008 Dec; 28(12):1523-30. PubMed ID: 19025433 [TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 5 inhibitors: are they cardioprotective? Reffelmann T; Kloner RA Cardiovasc Res; 2009 Jul; 83(2):204-12. PubMed ID: 19474180 [TBL] [Abstract][Full Text] [Related]
10. [Vasodilators in heart failure. Basis for their use]. Mesquita ET; Mady C Arq Bras Cardiol; 1994 Dec; 63(6):531-6. PubMed ID: 7605242 [No Abstract] [Full Text] [Related]
11. Phosphodiesterase type 5 inhibition: a support of the left ventricular assist device bridge to transplant. Semigran MJ Circ Heart Fail; 2008 Nov; 1(4):211-2. PubMed ID: 19808293 [No Abstract] [Full Text] [Related]
12. Tadalafil (Cialis) once a day for erectile dysfunction. Med Lett Drugs Ther; 2008 Apr; 50(1283):27-8. PubMed ID: 18391900 [No Abstract] [Full Text] [Related]
13. Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. Guglin M Curr Heart Fail Rep; 2011 Sep; 8(3):219-25. PubMed ID: 21556702 [TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms. Giuliano F Eur Urol; 2008 Jun; 53(6):1121-3; discussion 1123-4. PubMed ID: 18329786 [No Abstract] [Full Text] [Related]
15. [Current role of non-digitalis inotropic agents in acute and chronic treatment of heart failure]. Dei Cas L; Nodari S; Raddino R; Metra M; Pelà G; Nardi M Cardiologia; 1994 Mar; 39(3):209-15. PubMed ID: 8039201 [No Abstract] [Full Text] [Related]